Diagnosis Biotech was founded in 2020 in response to the COVID-19 pandemic to find ways to enable mass testing. We developed and validated Phone Screen Testing (PoST), a new low-cost and non-invasive method to test COVID-19 from smartphone screen samples. PoST was shown to be as accurate as nasopharyngeal sampling in identifying COVID-19 contagious people (PoST article).
We are now working on expanding the B2B and B2C COVID-19 testing service from Chile, where PoST was piloted, to LATAM, the UK and USA. In parallel, we are developing the first PoST machine that will take and analyse samples from phones to identify over 50 pathogens in 10 minutes. The aim is to generate a broad and distributed network of PoST machines to enable mass testing for epidemiological surveillance of all kinds of infectious diseases.